Immunome (IMNM) in the Pivotal Point Check: Phase 3 Success with Varegacestat in Desmoid Tumors - Significant Improvement in Progression-Free Survival and 56% Response Rate Pave the Way for FDA Approval 2026!
Reading Time: 3 minutes
The drug Varegacestat met the primary endpoint and significantly improved progression-free survival. The key secondary endpoints were also achieved, with an objective response rate of 56% for Varegacestat. The positive study results pave the way for a marketing application with the US FDA. Immunome is a biotechnology company focused on developing next-generation targeted cancer therapies. The stock soared after the release of highly positive topline data from the pivotal Phase 3 study RINGSIDE with Varegacestat in patients with...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
